Clinical manifestations and treatment considerations of herpes simplex virus infection

Journal of Infectious Diseases

Volumn 186, Issue SUPPL. 1, 2002, Pages

  Simmons, Anthony ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PREDNISONE; VALACICLOVIR;

CLINICAL FEATURE; CONFERENCE PAPER; DERMATOME; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; LUMBOSACRAL PLEXUS; PERIPHERAL NERVE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BELL PALSY; CENTRAL NERVOUS SYSTEM DISEASES; CORNEAL DISEASES; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNOCOMPETENCE; PERIPHERAL NERVOUS SYSTEM DISEASES; STOMATITIS, HERPETIC; TRIGEMINAL NERVE DISEASES;

EID: 0037108437     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342967     Document Type: Conference Paper

References (68)

1. World Health Organisation. Prevention and control of herpesvirus diseases. Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO meeting. Bull World Health Organ 1985:63:185-201.
2. Whitley RJ, Gnann JW. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman B. Whitley RJ. Lopez C, eds. The human herpesviruses. New York: Raven, 1993:69-105.
3. Whitley RJ, Kimberlin DW. Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-53.
4. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986;314:686-91.
5. Stevens JG. Human herpesviruses: a consideration of the latent state. Microbiol Rev 1989:53:318-32.
6. Leib DA, Coen DM. Bogard CL, et al. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 1989:63:759-68.
7. Mertz GJ, Coombs RW, Ashley R. et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: A prospective study. J Infect Dis 1988;157:1169-77.
8. Wald A, Zeh J, Selke S. et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-50.
9. Cassidy KA, Whitley RJ. New therapeutic approaches to the alphaherpesvirus infections. J Antimicrob Chemother 1997;39:119-28.
10. Weller S, Blum MR. Doucette M, et al.. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993:54:595-605.
11. Lafferty WE, Coombs RW. Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection: influence of site infection and viral type. N Engl J Med 1987;316:1444-9.
12. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997:314:1800-3.
13. Huff JC, Krueger GG, Overall JC Jr, Copel J, Spruance SL. The histopathologic evolution of recurrent herpes simplex labialis. J Am Acad Dermatol 1981:5:550-7.
14. Spruance SL, Overall JC. Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977;297:69-75.
15. Esmann J. The many challenges of facial herpes simplex virus infection. J Antimicrob Chemother 2001;47(Suppl 1):l7-27.
16. Bader C, Crumpacker CS, Schnipper LE, et al. The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis 1978:138:897-905.
17. Embil JA, Stephens RG, Manual FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J 1975:113:627-30.
18. Fiddian AP, Yeo JM, Stubbings R. Dean D. Successful treatment of herpes labialis with topical acyclovir. Br Med J (Clin Res Ed) 1983:286:1699-701.
19. Worrall G. Evidence for efficacy of topical acyclovir in recurrent herpes labialis is weak. BMJ 1996:313:46.
20. Raborn GW, McGaw WT. Grace M, Tyrrell LD, Samuels SM. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J Am Dent Assoc 1987:115:38-42.
21. Laiskonis A, Thune T, Neldam S, Hiltunen-Back E. Valacyclovir in the treatment of facial herpes simplex virus infection. J Infect Dis 2002; 186(Suppl 1):S66-70 (in this issue)
22. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double blind placebo-controlled trial. Ann Intern Med 1993;118:268-72.
23. Baker DA, Deeter RG, Redder K. Phillips JA. Valacyclovir effective for suppression of recurrent HSV-1 herpes labialis [abstract 464]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto) Washington, DC: American Society for Microbiology, 2000.
24. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000;26:50-4.
25. Gilbert S. Improving the outcome of facial resurfacing-prevention of herpes simplex virus type 1 reactivation. J Antimicrob Chemother 2001;47(Suppl 1):29-34.
26. Darougar S, Wishart MS, Viswalingam ND. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 1985;69:2-6
27. Falcon MG. Herpes simplex virus infections of the eye and their management with acyclovir. J Antimicrob Chemother 1983;12(Suppl B):39-43.
28. Falcon MG. Rational acyclovir therapy in herpetic eye disease. Br J Ophthalmol 1987;71:102-6.
29. Sudesh S, Laibson PR. The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections. Curr Opin Ophthalmol 1999:10:230-3.
30. Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol 2000:118:1030-6.
31. Harding SP, Rigal D, Easty D, Sarapa N. Weller S. Superior intraocular penetration of aciclovir from valaciclovir in comparison with oral aciclovir. J Antimicrob Chemother 1999:44(Suppl A):16.
32. Poirier RH, Kingham JD, de Miranda P. Annel M. Intraocular antiviral penetration. Arch Ophthalmol 1982:100:1964-7.
33. Furuta Y. Fukuda S, Chida E, et al. Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. J Med Virol 1998;54:162-6.
34. Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996;105: 371-8.
35. Grogan PM, Gronseth GS. Practice parameter: steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review). Neurology 2001;56:830-6.
36. Belongia EA, Goodman JL, Holland EJ, et al. An outbreak of herpes gladiatorum at a high school wrestling camp. N Engl J Med 1991;325:906-10.
37. Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin J Sport Med 1999:9:86-90.
38. Anderson BJ. Valacyclovir for suppression of recurrent herpes gladiatorum [abstract 465]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
39. Klotz RW. Herpetic whitlow: an occupational hazard. AANA J 1990;58: 8-13.
40. Rowe NH, Heine CS, Kowalski CJ. Herpetic whitlow: an occupational disease in practising dentists. J Am Dent Assoc 1982;105:471-3.
41. Manzella JP, McConville JH, Valenti W, Menegus MA, Swierkosz EM, Arens M. An outbreak of herpes simplex virus type 1 gingivostomatitis in a dental hygiene practice. JAMA 1984;252:2019-22.
42. Mohler A. Herpetic whitlow of the toe. J Am Board Fam Pract 2000;13: 213-5.
43. Schwandt NW, Mjos DP, Lubow RM. Acyclovir and the treatment of herpetic whitlow. Oral Surg Oral Med Oral Pathol 1987;64:255-8.
44. Mercey D, Mindel A. Screening pregnant women for genital herpes. Biomed Pharmacother 1990;44:257-62.
45. Meyer LJ, de Miranda P, Sheth N, Spruance S. Acyclovir in human breast milk. Am J Obstet Gynecol 1988;158:586-7.
46. Smith J, Robinson NJ. Global review of the age-specific prevalence of infection with herpes simplex virus types 1 and 2. J Infect Dis 2002;186 (Suppl I):S3-28 (in this issue).
47. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000;45(Suppl 3):1-8.
48. Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000;283:791-4.
49. Feder HM, Geller RW. Herpetic whitlow of the great toe. N Engl J Med 1992;326:1295-6.
50. Egan LJ, Bylander JM, Agerter DC, Edson RS. Herpetic whitlow of the toe: an unusual manifestation of infection with herpes type 2. Clin Infect Dis 1998;26:196-7.
51. Patel R. Progress in meeting today's demands in genital herpes: an overview of current management. J Infect Dis 2002;186(Suppl 1):S47 56 (in this issue).
52. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-6.
53. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110-6.
54. Patel R, Bodsworth N J, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997;73:105-9.
55. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10.
56. Stanberry L, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30:549-66.
57. Spruance SL, Tyring S, Bleazard C, et al. Immunomodulation to decrease recurrences of herpes genitalis: a double-blind, dose ranging study of topical R-848 [abstract 466]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
58. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247-52.
59. Pass R, Weber T, Whitley RJ, eds. Management strategies in herpes: herpesvirus infections in pregnancy. Worthing, UK: PAREXEL MMS Europe, 2000.
60. Bork K, Bräuninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988;19:1024-9.
61. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993;128:542-5.
62. Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995;132:267-70.
63. Choy AC, Yarnold PR, Brown JE, Kayaloglou GT, Greenberger PA, Patterson R. Virus induced erythema multiforme and Stevens-Johnson syndrome. Allergy Proc 1995;16:157-61.
64. Davis LE, McLaren LC. Relapsing herpes simplex encephalitis following antiviral therapy. Ann Neurol 1983;13:192-5.
65. Ferrante P, Mancuso R, Pagani E, et al. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J Neurovirol 2000: 6(Suppl 2):S109-14.
66. Cornford ME, McCormick GF. Adult-onset temporal lobe epilepsy associated with smoldering herpes simplex 2 infection. Neurology 1997;48:425-30.
67. Chan PK, Chow PC, Peiris JS, Mak AW, Huen KF. Use of valaciclovir in a 12-year-old boy with herpes simplex encephalitis. Hong Kong Med J 2000;6:119-21.
68. Bergstrom T. Several options for antiviral treatment trials in multiple sclerosis-but which targets should be selected? Expert Opin Pharmacother 2000;1:1087-90.